1) Experimental drug 
Darusentan (LU-135252; HMR-4005) is an endothelin receptor antagonist. Gilead Colorado, a subsidiary of Gilead Sciences, under license from Abbott Laboratories, is developing darusentan for the potential treatment of uncontrolled hypertension. In June 2003, Myogen licensed the compound from Abbott for its application in the cancer field. In May 20...